Purpose

By doing this study, researchers hope to see if creatine monohydrate is a helpful treatment for people with Alzheimer's disease.

Condition

Eligibility

Eligible Ages
Between 60 Years and 90 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Diagnosed cognitive impairment due to Alzheimer's disease - Agreed cooperation from a study partner - Speaks English as primary language - Age 60 to 90 - Stable medication for ≥30 days - BMI ≥ 20.0kg/m2

Exclusion Criteria

  • Insulin-requiring diabetes, cancer requiring chemotherapy or radiation within the past 5 years, or recent cardiac event (i.e., heart attack, etc.) - Other neurodegenerative disease - Ongoing renal disorder or abnormal renal or liver function - Unable to undergo MRI - Clinical trial or investigational drug or therapy participation within 30 days of the screening visit - Non-English speakers - Inability to perform strength testing - Weight > 350 lbs.

Study Design

Phase
N/A
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Creatine Monohydrate Arm
This study a single arm intervention. All participants will receive 20 grams of creatine monohydrate daily for the whole intervention (8 weeks).
  • Dietary Supplement: Creatine Monohydrate
    Participants will take 20 grams of creatine monohydrate daily for 8 weeks.The 20 grams will be divided into two equal 10 gram doses that will be stirred into a beverage. One 10 gram dose will be taken in the morning and the other 10 gram dose in evening.

Recruiting Locations

University of Kansas Medical Center
Kansas City, Kansas 66160
Contact:
Aaron Smith, MS
913-229-5935
asmith71@kumc.edu

More Details

Status
Recruiting
Sponsor
University of Kansas Medical Center

Study Contact

Aaron N Smith, MS, RD
913-229-5935
asmith71@kumc.edu

Detailed Description

Alzheimer's disease is a progressive brain disorder that causes memory and thinking problems. Current medications may temporarily help with symptoms but cannot stop the disease from getting worse. As such, new treatments that slow or stop the disease from progressing are needed. There is some evidence from animal studies that taking creatine monohydrate may improve thinking in Alzheimer's disease and be good for brain health. However, no studies have looked at creatine monohydrate supplementation in humans with Alzheimer's. Creatine monohydrate is a dietary supplement regulated by the FDA. This is a study that will test if taking creatine monohydrate may be a helpful treatment for people with Alzheimer's disease. In this study, investigators will will evaluate: 1. Whether persons with Alzheimer's disease are able to easily take creatine monohydrate for 8 weeks. 2. Whether creatine monohydrate affects thinking function in people with Alzheimer's Disease. 3. Whether creatine monohydrate affects certain biochemicals in the brain and body. 4. Whether creatine monohydrate improves muscle size and strength.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.